Who’s getting left behind in the weight loss bonanza?
The market for glucagon-like peptide-1 (GLP-1) agonists such as Ozempic and Wegovy is soaring, but their success could be a detriment to competing drugs, devices and procedures, according to a new report from global strategy and management consulting firm …